Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Henry MD
David Henry MD Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Interview · October 31, 2013

Genomic Testing: New Frontier in Cancer Therapy

Axel Grothey MD
Lee Schwartzberg MD, FACP

 

 Save  Recommend
 Share

Additional Info

  1. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328-337.

  2. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338-345.

  3. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346-354.

  4. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355-364.

  5. Klein CA. Selection and adaptation during metastatic cancer progression. Nature. 2013;501(7467):365-372.

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Lee Schwartzberg MD, FACP

Further Reading

Most Read This Week

Recently Updated